Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Sectors  >  Healthcare

News : Sectors

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors
06:48aCSL : Initial Director's Interest Notice
PU
05:49aFDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch
AQ
05:48aRAMSAY HEALTH CARE : ASX Announcement - CARES Notification of dividend / distribution
PU
04:58aMEDTRONIC : Founder Earl Bakken Passes Away at Age 94
AQ
04:51aNEVRO 24 HOUR DEADLINE ALERT : Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against Nevro Corp. - NVRO
BU
04:31aINCYTE : Lilly And Incyte Update Safety Analysis Of OLUMIANT
AQ
04:13aONO PHARMACEUTICAL : Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer (47.1KB)
PU
03:08aDAIICHI SANKYO : Presents Updated Results of Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress
PU
02:09aNATIONAL MEDICAL CARE CO. : Announces Resignation and Appointment of a CEO
AQ
01:55aMMJ PhytoTech Ltd Investor Presentation
AW
01:50aMMJ PhytoTech Ltd MediPharm Labs Management Team Appointments
AW
01:46aMMJ PHYTOTECH LTD (ASX : MMJ) MediPharm Labs Management Team Appointments
AQ
12:48aACR 2018 : Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis
PU
10/21Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
GL
10/21MERCK AND : BiolineRX tanks on trial results
AQ
10:26aSELVITA : Polish companies using ground-breaking treatment in fight against cancer
AQ
10:11aNetScientific (NSCI); portfolio company receives $10m investment for 40% stake
AQ
10:01aUNITED THERAPEUTICS : CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
PR
10:01aCOLLPLANT : and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
PR
10:01aAC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence
GL
09:33aALMIRALL : LLC Launches New Name at Fall Clinical Dermatology Congress
PU
09:25aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
09:25aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
09:21aBRISTOL MYERS SQUIBB : Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma
BU
09:20aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
09:20aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
09:16aGENENTECH : ’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone
BU
09:16aNOVARTIS : COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
AQ
09:16aBRISTOL MYERS SQUIBB : Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer
BU
09:15aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
09:01aKAROLINSKA DEVELOPMENT : portfolio company OssDsign announces FDA clearance for Cranioplug
AQ
08:45aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
08:45aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
08:40aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
08:40aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
08:35aECKERT & ZIEGLER STRAHLEN- UND MEDIZINTECHNIK AG : Notification and public disclosure of transactions by persons
EQ
08:33aOXURION : Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project
PU
08:26aHSI opens up 106 pts at 25,668; H-share up 51 pts at 10,273
AQ
08:23aREDX PHARMA : ROCK2 inhibitors poster to be presented
PU
08:18aSHIRE : Form 8.3 - Takeda Pharmaceutical Company Limited
PU
08:16aWIDECELLS : CellPlan deal with Smart Cells
PU
08:16aMICROPORT SCIENTIFIC : Experts from Pakistan Society of Interventional Cardiology Visit...
PU
08:16aMICROPORT SCIENTIFIC : ® Orthopedics Holds First University of Hong Kong - Sh...
PU
08:16aMICROPORT SCIENTIFIC : ® Takes Firehawk® to Encore Seoul 2018 in Korea
PU
08:16aC4X DISCOVERY : PDMR Shareholding
PU
08:15aASTRAZENECA : to present new data demonstrating breadth of research portfolio in renal disease at ASN Kidney Week 2018
PU
08:15aSHIRE : Form 8.3 - Shire Plc
PU
08:12aROYAL PHILIPS : Philips initiates share repurchase program for up to 5 million shares to cover its long-term incentive and employee stock purchase plans
PU
08:12aHISAMITSU PHARMACEUTICAL : Notification of the commencement of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)
PU
08:12aSYSMEX : Strengthening Our Global R&D Structure to Foster Early-Stage Innovation
PU
08:05aAGENNIX AG I.L. : Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQ
08:05aAGENNIX AG I.L. : Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQ
08:03aORYZON GENOMICS : to present at upcoming international conferences
PU
08:02aMEDISTIM : Final results from the REQUEST study presented at EACTS
AQ
08:01aASTRAZENECA : Lynparza shows 70% reduction in PFS ovarian cancer
AQ
08:01aHERANTIS PHARMA OYJ : Manager's Transactions - Pekka Simula
AQ
07:43aEPIGENOMICS : Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics’ colorectal cancer screening blood test Epi proColon®
PU
07:35aEPIGENOMICS AG : Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics' colorectal cancer screening blood test Epi proColon(R)
EQ
07:31aDBV TECHNOLOGIES : Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration
AQ
07:13aTAKEDA PHARMACEUTICAL : Investigational Subcutaneous Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Ulcerative Colitis
PU
07:08aROYAL PHILIPS : Philips' Third Quarter Results 2018
PU
07:08aDOTTIKON ES : Considerably Lower Net Sales and Net Income
PU
07:05aKuros Biosciences obtains US patent covering a method for producing osteoinductive materials
TE
07:00aADDEX THERAPEUTICS : Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy (Review Published in Epilepsia Journal)
AQ
06:48aCSL : Final Director's Interest Notice
PU
Discover
10:29aMERCK AND : `s STING agonist shows positive action in early-stage cancer study
AQ
10:29aEXELIXIS : Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma
AQ
10:29aLABORATORY OF AMERICA : LabCorp, AstraZeneca subsidiary team up for precision medicine development
AQ
10:28aPIRAMAL ENTERPRISES : denies loan defaults by real estate developers
AQ
10:26aBRISTOL MYERS SQUIBB : Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden 10 mut/Mb
AQ
1  2  3  4  5  6  7  8  9  10Next
Advertisement